Despite recent Level 1 evidence on the benefits of adjuvant radiotherapy for locally advanced prostate cancer (PCa), the timing and decision to administer adjuvant radiotherapy post-radical prostatectomy (post-RP) remains debatable, particularly for patients with focal extraprostatic extension (EPE) and/or focal positive surgical margins (PSMs). In this study, we assess the utility of detailed pathological assessment of EPE and PSM, as this may influence the criteria for instituting adjuvant radiotherapy. A total of 148 RP cases (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001) were identified retrospectively as having EPE and/or PSM. All slides were re-reviewed, incorporating recent proposals by the Collage of American Pathologists (CAP) for the reporting of EPE and PSM, and correlated with clinical data. Both EPE and PSM were found to be independent predictors of biochemical failure (BCF); however, only EPE was associated with metastasis and death. BCF was also more likely to be associated with cases that had non-focal EPE than focal EPE. Similarly, non-focal PSM cases had a significantly higher risk of BCF than focal cases. Our study confirms the value of detailed pathological assessment of EPE and PSM post-RP. The results support the concept of selective adjuvant radiotherapy in patients with EPE and PSM, based on focality and extent.
Introduction
The timing and decision to administer adjuvant radiotherapy post radical prostatectomy (post-RP) for prostate cancer (PCa) remains debatable, particularly for patients with focal extraprostatic extension (EPE) and/or focal positive surgical margin (PSM). For example, although some studies [1] [2] [3] [4] have found that immediate adjuvant treatment decreased the risk of biochemical failure (BCF) in patients with PSM and extracapsular tumor extension, it is not entirely clear what its effects are on distant metastasis and survival, in spite of one recent report (SWOG 8794 study) indicating a statistical advantage for early adjuvant radiotherapy. The SWOG study stated that adjuvant radiotherapy resulted in significantly reducing the risk of PSA relapse and disease recurrence compared to the 'wait and see' approach (median PSA relapse-free survival was 10.3 years for adjuvant therapy vs 3.1 years for observation and median recurrence-free was 13.8 years for adjuvant therapy vs 9.9 years for observation). This has led to the recommendation of adjuvant radiotherapy for 'high risk' patients' post-RP. However, the debate on timing of radiotherapy, especially for patients in the 'non-high risk' categories, is far from settled, as evidenced by the on-going multicentered randomized 'RADICALS' clinical trial. 5 In this study, we attempt to determine whether a more detailed pathological assessment of EPE and PSM may help to refine the criteria for instituting adjuvant radiotherapy, emphasis was placed on prognostic diversity between focal EPE/PSM versus non-focal EPE/PSM. EPE is simply defined as tumor outside the normal confines of the prostate, 6, 7 however, the pathological reporting of EPE is far from simple particularly with the incorporation of new recommendations by the College of American Pathologists (CAP). First, the CAP has suggested that EPE be subdivided into focal and nonfocal types as multiple studies have indicated that focal EPE is associated with a better prognosis. [8] [9] [10] [11] It remains unresolved, however, as to which of the many definitions for EPE focality should be incorporated into the decision-making algorithm on adjuvant radiotherapy. Second, the histological criteria for diagnosis of EPE has been expanded from tumor in fat to include tumor at the level of fat, neurovascular bundle involvement, bulging nodule and tumor beyond the normal confines of the prostate. It remains to be seen whether all or some of these subtypes should be equated with the term EPE as studies comparing their individual prognostic significances are lacking.
Regarding PSM, formerly, a margin may have been labeled as being positive if the tumor was extremely close to the resection margin. Presently, a margin is only considered positive if there is a tumor in actual contact with the resection margin. 6, 12 Although, previous studies have shown that the presence of a PSM carries with it prognostic significance, 13, 14 it is not entirely clear which patients with PSM should receive adjuvant therapy. The CAP has recommended measuring the total linear length of PSM in mm as this provides additional prognostic information that may aid in this decision-making process. Several studies have found that patients with focal/short PSM possess a better prognosis than patients with non-focal/longer PSM, 10, [15] [16] [17] [18] [19] [20] though definitions for PSM focality are highly variable with no consensus.
The CAP also recommends specifying whether or not PSM and EPE are present at the same location within RP. 6 In theory, the presence of these two features at the same location may suggest a more locally advanced tumor, which is not amenable to complete excision due to extensive EPE. In contrast, the presence of these features at different locations may suggest an iatrogenic incision made by the surgeon in a situation where EPE is localized and amenable to complete wide excision. This possible dichotomy has not been previously explored in the urologic literature.
Finally, although, assessment of the independent and additive prognostic significance of PSM and EPE has been evaluated previously by researchers such as by Cheng et al., 21 no study has re-evaluated this significance after incorporating the new CAP recommendations.
Herein, we attempted to address these issues by retrospectively re-reviewing archived RP cases sufficiently remote to provide meaningful follow-up data. Our objectives were as follows: (1) to determine the independent and additive prognostic significance of EPE and PSM using the latest CAP recommendations; (2) compare focal to non-focal EPE by applying different previously suggested definitions of focality; (3) elucidate the prognosis of different EPE subtypes; (4) determine the significance of different PSM lengths in an attempt to elucidate focality of PSM and (5) assess the prognostic significance of having EPE and PSM present at the same location.
Materials and methods
The surgical pathology reports of all open retropubic RP performed from 1993 to 2001 by a single surgeon (Chin JL) were reviewed. Out of 900 consecutive cases, 213 were identified as having EPE or PSM or a combination thereof. Cases with a history of neoadjuvant hormone therapy (n ¼ 48), incomplete slide sets or no clinical data (n ¼ 11 and 6, respectively) were excluded. RP specimens had been processed in accordance with guidelines of that time period.
All slides (n ¼ 4844) from the 148 cases were rereviewed (Chan SM). The following pathologic features were determined: Gleason score based on the 2005 ISUP guidelines, 22 seminal vesicle invasion (SVI), lymphovascular invasion, lymph node metastasis, tumor volume in percentage (assessed by visual inspection), margin status and presence or absence of EPE. All slides identified as having PSM and/or EPE were further re-reviewed (Moussa M and Gabril MY). For EPE, location (apex, anterior, lateral, posterior, posterolateral and/or bladder neck), subtype (in fat, at the level of fat, neurovascular bundle involvement, beyond the normal confines and/or bulging nodule) and focality were assessed. Focal EPE was defined in three ways: (1) Epstein et al. 8 definition: a few neoplastic glands exterior to the prostate, (2) Wheeler et al.
9 definition: tumor outside the prostate involving less than one high-power field in 1-2 sections, and (3) a simplified definition introduced by our group for the purpose of this study: 'EPE confined to one slide only'. Non-focal EPE was EPE beyond the aforementioned focal definitions. For PSM, the location was recorded and the total linear length of margin positivity in mm was measured at 100 Â power using Spot Advanced Imaging Software version 4.6 (Diagnostic Instruments, Sterling Heights, MI, USA), which allows taking digital images of slides. From these images, we manually traced out all areas where tumor touched the inked resection margin and measured ( Figure 1 ). These measurements were recorded by the software in mm and then aggregated to produce the total length of the PSM.
To better analyze the significance of EPE relative to PSM, cases were categorized into four groups:
Clinical follow-up data
Clinical data were obtained (Garcia FJ) from patient records and included the following: age, preoperative PSA, length of follow-up, presence or absence of BCF (defined as three consecutive rises in PSA with a minimum PSA level of X0.1 ng/ml), time to BCF, presence or absence of non-lymph node metastasis, Extraprostatic extension and margin status in radical prostatectomies for PCa SM Chan et al latest survival data, most likely cause of death (PCa or other), presence or absence of adjuvant or salvage radiotherapy or hormone therapy. All patients had been followed clinically post-RP either by the attending surgeon or the local referring urologist (who usually provided clinical update to our center). The frequency of urologic follow-up was individualized and risk-adjusted, with a minimum of every 6 months, for a period of up to 7 years. If clinically free of disease beyond 7 years, follow-up was reverted to the primary care physician. Overall, for all four groups combined, the mean follow-up was 97 months and the median follow-up was 99 months.
Statistical analysis
Clinical data were compared across the four groups using analysis of variance for differences in age and preoperative PSA, Fisher's exact test for Gleason score and tumor volume, and log-rank test for 5 year BCF rate. Risk of BCF, metastasis and survival among the four groups was compared using the w 2 -test. Univariate and multivariate analyses were performed using Cox regression model to evaluate the predictive value of PSM and EPE on BCF. The probability of freedom from BCF for the four groups was estimated with the Kaplan-Meier method. To study the prognostic significance of the length of a PSM, cases were categorized into three groups based on PSM length: (1) o0.1 mm, (2) 0.1-1.0 mm, (3) 41.0 mm and comparisons were made with respect to BCF using Fisher's exact test. Fisher's exact test was also used for comparison of EPE and PSM at the same location versus different locations. All tests were two-sided, with a P-value of o0.05 considered to be significant.
Results

Prognostic significance of EPE and PSM
In all, 120 out of 148 cases (cases with SVI and/or lymph node metastasis (n ¼ 17) and unknown lymph node status (n ¼ 11) were excluded) were divided into four groups with patient characteristics for each group listed in Table 1a . There was no significant difference in median age, median preoperative PSA or Gleason score among the four groups. The 5-year BCF rate was significantly different among the four groups with a rate of 51.5% in cases with þ EPE þ Margin versus 11.0% in cases with ÀEPEÀMargin (P ¼ Extraprostatic extension and margin status in radical prostatectomies for PCa SM Chan et al received adjuvant treatment and the P-value for BCF among the four groups was still significant (P ¼.007). Table 1b shows correlations of the four groups to BCF, metastasis and survival. Particularly note-worthy was the fact that the rates of metastasis and survival were 13.9 and 97.1%, respectively, in the group with þ EPEÀMargin, whereas, the group with ÀEPE þ Margin group had no cases of metastasis or death. BCF free survival analysis for the four groups is presented in Figure 2 .
To further evaluate PSM and EPE, univariate and multivariate analyses were performed. In the univariate analysis, þ EPE (hazard ratio 2.52, 95% confidence interval (CI) 1.17-5.44, P ¼ 0.018), þ Margin (hazard ratio 2.23, 95% CI 1.12-4.44, P ¼ 0.022), Gleason score X8 (hazard ratio 2.88, 95% CI 1.11-7.50, P ¼ 0.03) and tumor volume 45% (hazard ratio 2.88, 95% CI 1.01-8.22, P ¼ 0.048) were all significant predictors of BCF but Gleason score X7 (hazard ratio 0.85, 95% CI 0.38, 1.89, P ¼ 0.6) was not. In the multivariate analysis controlling for EPE, surgical margin and Gleason score, þ EPE (hazard ratio 2.68, 95% CI 1.23-5.82, P ¼ 0.013), þ Margin (hazard ratio 2.53, 95% CI 1.25-5.13, P ¼ 0.010) and Gleason score X8 (hazard ratio 3.61, 95% CI 1.35-9.70, P ¼ 0.010) were all independent predictors of BCF. Also, tumor volume was a significant predictor when employed as a continuous variable in a univariate analysis (P ¼ 0.014).
Focal and non-focal EPE
The 85 RP with EPE were categorized as having focal or non-focal EPE using the criteria by Epstein et al., Wheeler et al. and our simplified definition. Listed in Table 2 , is the incidence of focal and non-focal EPE under different definitions and the proportion of focal and non-focal EPE in cases with BCF, metastasis and death.
EPE histological subtypes
Of 85 cases with EPE, the vast majority contained multiple EPE subtypes with the two most common subtypes being tumor in fat and neurovascular bundle involvement. Accordingly, the most common subtypes encountered in cases of metastasis (n ¼ 18) and death (n ¼ 9) were also tumor in fat (present in 94% of cases with metastasis and 89% of cases with death) and neurovascular bundle involvement (present in 72 and 78%, respectively).
PSM Length
The 43 RP with PSM and no SVI or lymph node metastasis were divided into two groups based on PSM length. Out of 43 patients with PSM, 40 had data regarding whether or not they received adjuvant therapy. Overall, 16 out of 40 (40%) received adjuvant therapy, 6 out of 40 (15%) received salvage therapy. In 50% and 36.7% of cases with o0.1 and X0.1 mm PSM, respectively, received adjuvant therapy.
BCF rates were significantly higher in cases with nonfocal PSM length X0.1 mm (51.5%) than in cases with total focal PSM length o0.1 mm (10.0%), (P ¼ 0.028). A BCF free survival analysis with the two groups is presented in Figure 3a . Furthermore, cases were divided into three groups: (1) o0.1 mm, (2) 0.1-1.0 mm, (3) 41.0 mm (Figure 3b ) and there was no significant difference in BCF between the 0.1-1.0 mm, and 41.0 mm groups (PX0.9).
Location of concurrent EPE and PSM
The 25 RP specimens with both EPE and PSM were separated into two groups: (1) EPE and PSM at the same (2) different locations. There was no significant difference Extraprostatic extension and margin status in radical prostatectomies for PCa SM Chan et al in BCF rates (53 versus 50%) between the groups (P40.9). The most common sites for EPE and PSM to be located together were the posterior and posterolateral regions.
Discussion
The role of adjuvant radiotherapy post-RP in patients with EPE or PSM, particularly focal type, is debatable. This study assesses the clinical significance of an in-depth pathological assessment of EPE and PSM that incorporates new CAP recommendations as this may influence the criteria for instituting adjuvant radiotherapy as opposed to deferring therapy. Also we investigate the prognostic significance of focality of EPE and PSM. Three randomized multi-centre trials comparing adjuvant radiotherapy versus no adjuvant treatment for post-RP patients who had either EPE, PSM, SVI, or a combination thereof, showed fewer and/or later BCF, metastasis development and longer progression-free survival for those who received adjuvant radiotherapy. 1, 2, 3, 23 The Southwest Oncology Group (SWOG) study by Thompson et al.,
2 with longer follow-up, recently also showed an overall survival benefit with adjuvant radiotherapy compared with the 'wait and see' approach. No studies, however, have compared adjuvant therapy with early salvage therapy before PSA failure, an issue which is being addressed with another multi-center randomized controlled trial (the 'RADICALS' study). 5 
Prognostic significance of EPE and PSM
Utilizing the latest CAP criteria for EPE and PSM, the 5-year BCF free survival rate was 48.5% for þ EPE þ Margin cases versus 89.0% for ÀEPEÀMargin cases. Our results concur with findings by Cheng et al. 21 who reported a 5-year progression free survival of 55% for þ EPE þ Margin cases and 90% for ÀEPEÀMargin cases. Though both EPE and PSM were associated with a higher risk of BCF in our study, only cases with EPE were associated with metastasis and death. In contrast, none of the cases with PSM only, developed metastasis or death from PCa, thus, suggesting an iatrogenic surgical event as opposed to inherent biologic tumor factor. Furthermore, our study found that EPE, PSM and Gleason ScoreX8 were all independent predictors of BCF in univariate and multivariate analyses while excluding cases with SVI and/or lymph node metastasis.
Focal and non-focal EPE and subtypes of EPE
Although patients with EPE may benefit from adjuvant therapy, in a subset of patients with focal EPE, the use of early adjuvant therapy may be unnecessary. Multiple studies, including our own, have shown that focal EPE has a much better prognosis than non-focal EPE. 8, 9 As there is no consensus definition established for focal EPE, our study compared Epstein's 8 and Wheeler's 8,9 criteria and introduced a third definition for focal EPE as 'EPE confined to one slide only'. Although, focal EPE had a favorable prognosis compared with non-focal EPE under all three definitions, only Epstein's and Wheeler's definitions were successful at separating out cases that had little to no risk of clinical progression from those at higher risk. With respect to EPE subtypes, most of the prostatectomies in this study contained multiple EPE subtypes, thus eliminating the likelihood of detecting differences, if any, of the prognostic significance for each subtype.
The prognostic significance of PSM length
Regarding PSM, although a PSM has been shown to be an independent predictor of BCF, the decision to administer adjuvant treatment for PSM remains unclear. Lake et al. 24 found that focal positive margin after RP conferred a decreased disease free survival even in patients with otherwise organ-confined disease. However, the definition of 'focal positive margin' for this study was more generous: 'less than or equal to 3 mm'.
To refine the decision-making process on adjuvant therapy based on PSM, some have suggested triaging patients based on the total linear extent of the PSM. 10, [15] [16] [17] [18] [19] [20] Suggested PSM cutoff points have ranged from 1 15 to 3 mm 10, 16, 17, 20 to 6 18 to 10 mm 19 . Of note from our study is the finding that patients with a total PSM length X0.1 mm (non-focal), had a significantly higher risk of BCF (51.5%) than patients with total PSM length o0.1 mm (focal) (10.0%). Contrary to previous studies, however, measurements were only taken where tumor physically touched the resection margin by using computer software. This method is arguably more objective than methods used previously, and may render results more reproducible and facilitate comparison between studies. The disadvantage of this approach, however, is it requires commercially available computer software programs.
Location of concurrent EPE and PSM
The presence of both EPE and PSM in RP is known to be associated with a poor prognosis. 21 Theoretically, having these two features at the same location may portend a worse prognosis versus different locations. Our results, pending verification with larger studies, however, indicate that there is no statistically significant difference in BCF rates between the two groups. Thus, it may not be necessary to report this finding as suggested by the CAP. 6 Several limitations of this study need to be addressed. An obvious issue is that some patients received adjuvant therapy. However, groups with the highest and second highest utilization rates of adjuvant therapy ( þ EPE þ PSM and þ EPEÀMargin, respectively) still developed the highest and second highest rates of BCF, metastasis and death. Thus, the effect of adjuvant therapy on our results would either be that of no effect or more likely, resulted in muting the differences across the four groups in terms of BCF, metastasis and death. Similarly, Swindle et al. 25 argued that removal of cases with adjuvant therapy may distort recurrence rates by excluding cases at higher risk of recurrence. A second limitation of this study is our small sample size, especially when dealing with subgroup analysis for the different questions addressed. Future studies with larger numbers are necessary for validation of our results.
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Conclusion
Our study confirms the value of providing a more detailed pathological assessment of EPE and PSM in RP as it may help to refine the criteria for instituting adjuvant radiotherapy. Our results confirm that (1) EPE and PSM are both independent predictors of BCF but only EPE is associated with metastasis and death from PCa. In addition, patients with þ EPE þ Margin or þ EPEÀMargin had higher risks of BCF, metastasis and death from PCa than patients with ÀEPE þ Margin or ÀEPEÀMargin. (2) BCF was also more likely to be associated with cases that had non-focal EPE than focal EPE. (3) We could not elucidate prognostic differences in the EPE subtypes. (4) Patients with a non-focal PSM X0.1 mm had a significantly higher risk of BCF compared with those with a focal PSM o0.1 mm.
(5) EPE and PSM at the same location within the prostate had no statistically significant difference in BCF rates compared with EPE and PSM at different locations. The results support the concept of risk stratification in patients with EPE, based on focality and extent of EPE as well as the length of PSM. We support the ongoing randomized trial 5 to elucidate the relative benefits and morbidity of adjuvant radiotherapy versus early salvage radiotherapy but for patients who are not eligible or not willing to enroll in the study; findings from this study may provide a useful clinical guide to adjunctive therapy after RP, pending validation from further studies.
